---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-22-000050"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2022-08-30T23:59:59+00:00"
generated_at: "2026-06-23T19:53:42.235611+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Neurocrine to acquire Diurnal Group for £48.3M cash

## Summary
- Acquiring entire issued share capital of Diurnal for ~£48.3M (~$56.5M) in an all-cash transaction.
- Transaction conditional on approval by Diurnal shareholders and other customary closing conditions.
- Neurocrine expects deal to accelerate establishment of UK clinical development and commercial capabilities.
- Announcement made under Rule 2.7 of the UK City Code on Takeovers and Mergers.

## SEC filing metadata
- accession: 0000914475-22-000050
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2022-08-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447522000050/0000914475-22-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447522000050/nbix-20220830.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-22-000050
- JSON: https://secwatch.observer/filing/0000914475-22-000050.json
- Plain text: https://secwatch.observer/filing/0000914475-22-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.